CSPC Pharma (01093) has announced that the group will present 8 latest clinical trial advances at the European Society for Medical Oncology (ESMO) Annual Congress, taking place in Madrid, Spain from October 23 to October 27, 2026, with 2 of them selected as Late-breaking Abstracts (LBA).

The 8 clinical advances selected for this congress will be presented in the form of 1 preferred oral presentation, 3 rapid oral presentations, 3 posters, and 1 e-poster, covering tumor types including breast cancer, lung cancer, gastric cancer, liver cancer, colon cancer, pancreatic cancer, and perivascular epithelioid cell tumors, fully demonstrating the group's R&D strength and clinical research capabilities in the field of oncology treatment.